more_reports

The Latest Healthcare Services Articles from Streetwise Reports

AI Healthcare Co. With 'Bright' Outlook Closes Placement

  ()
Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million. Find out why one analyst says the stock is a Strong Buy and worth going overweight on.

Is This AI Healthcare Stock Worth Being Overweight On?

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.

AI Collaboration to Streamline Healthcare Administration and Improve Patient Outcomes

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers.

Long Term Care Co.'s Target Price Raised

Research Report
  ()
Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results.

AI Healthcare Co. Signs Partnership With Large Regional Health Plan

Research Report
  ()
Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note.

Healthcare AI Company Achieves Key Milestones and Secures New Partnerships

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects.

Is This Pharma Co. the Next Eli Lilly?

  ()
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly.

Positive Phase 2 Clinical Trial Results Announced for Drug Treating Idiopathic Hypersomnia

  ()
Zevra Therapeutics Inc. (ZVRA:NASDAQ), a company specializing in rare disease therapeutics, has announced positive final results from its Phase 2 clinical trial evaluating the safety and tolerability of KP1077 for treating idiopathic hypersomnia.

Co. Targets More Verticals in Safe Supply

  ()
This Canadian firm, with a streaming business model, intends to invest in two additional segments of the safe supply ecosystem. Here, learn more about this approach to reducing harms from illegal drugs.

Co. Expands Telehealth Contract to New State

  ()
Reliq Health Technologies Inc. announced that a large U.S. health group has expanded its contract with the telehealth company to cover facilities in a new state. Read why one analyst thinks the stock is a Buy.

New Healthcare AI Partnership Aims to Transform Health Risk Assessments

  ()
Treatment.com AI Inc. has entered into a collaborative agreement with Health Care Services International Inc. to leverage its advanced healthcare AI engine and enhance services. Read on to learn what this means for the growing sector.

Investor Conference Highlights New Strategic Directions for Addressing Opioid Crisis

  ()
Safe Supply Streaming has provided an update on Safety Strips, its recent acquisition. Read on for more about how this impacts the company's battle against the opioid crisis.

Medical School Renews Contract with Tech Co.

  ()
This move further validates the firm's Medical Education Suite. Discover why one analyst rates this healthcare-disrupting company as a Strong Buy.

Showing Results: 1 to 13 of 13